The impact of Clonidine, a pharmacological treatment for attention deficit hyperactivity disorder (ADHD), on behavioural and brain imaging measures of attention, inhibition and error processing.
Phase 4
Recruiting
- Conditions
- Study employs a commonly used ADHD medication (Clonidine) with healthy human adults (only) and examines changes in behaviours that are of relevance to ADHD (inhibition, error processing, selective attention)Mental Health - Other mental health disorders
- Registration Number
- ACTRN12615000093583
- Lead Sponsor
- Professor Mark Bellgrove
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 26
Inclusion Criteria
healthy adult
Normal or corrected to normal vision
Exclusion Criteria
History of psychiatric illness
Currently on medication
Smoker
Regular recreational drug use
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method mean stop signal reaction time (SSRT) - a measure of response inhibition<br>[At approx 90-180 minutes following placebo vs Clonidine administration<br>];number of errors on error awareness task (EAT)<br>[Approximately 90-180 minutes following Placebo vs Clonidine administration];Mean asymmetry measure - spatial asymmetry task<br>[At approx 90-180 minutes following placebo vs Clonidine administration]
- Secondary Outcome Measures
Name Time Method amplitude of the Error positivity (Pe) - an electrophysiological (EEG) correlate of error awareness (see primary outcome 2) [At approx 90-180 minutes following placebo vs Clonidine administration];amplitude of the Error related negativity (ERN) - an electrophysiological (EEG) correlate of error processing (see primary outcome 2) [At approx 90-180 minutes following placebo vs Clonidine administration];EEG measure of (pre-target) alpha power spatial asymmetry (see primary outcome 3)[At approx 90-180 minutes following Placebo vs Clonidine administration]